Printer Friendly

Boehringer Ingelheim signs collaboration and licence agreement with Bridge Biotherapeutics.

M2 EQUITYBITES-July 22, 2019-Boehringer Ingelheim signs collaboration and licence agreement with Bridge Biotherapeutics


Germany-based Boehringer Ingelheim has signed a new collaboration and licence agreement with Korea-based Bridge Biotherapeutics to produce autotaxin inhibitor BBT-877, intended to treat patients with fibrosing interstitial lung diseases, it was reported on Friday.

Currently, BBT-877 is under phase I clinical studies and is expected to enter phase II testing within one year. The product is the company's autotaxin inhibitor being developed to treat various fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis.

According to the contract, Bridge Biotherapeutics will receive upfront and near term payments of EUR45m. Bridge will also receive more than EUR1.1bn based on the achievement of specific development, regulatory and commercial milestones, In addition, it is eligible to receive double-digit royalties.

((Comments on this story may be sent to

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jul 22, 2019
Previous Article:Community Heritage Financial declares dividend of USD0.03 per share for Q2 2019.
Next Article:Columbia Care's board approves USD25m repurchase plan.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters